Banco Santander S.A. purchased a new position in Becton, Dickinson and Company (NYSE:BDX – Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 3,205 shares of the medical instruments supplier’s stock, valued at approximately $574,000.
Several other institutional investors and hedge funds have also bought and sold shares of BDX. Maryland Capital Advisors Inc. grew its position in shares of Becton, Dickinson and Company by 13,900.0% in the 3rd quarter. Maryland Capital Advisors Inc. now owns 140 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 139 shares during the period. Trifecta Capital Advisors LLC lifted its position in Becton, Dickinson and Company by 59.0% during the 3rd quarter. Trifecta Capital Advisors LLC now owns 167 shares of the medical instruments supplier’s stock valued at $30,000 after acquiring an additional 62 shares during the period. Meeder Asset Management Inc. lifted its position in Becton, Dickinson and Company by 152.2% during the 1st quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock valued at $27,000 after acquiring an additional 102 shares during the period. Bell Investment Advisors Inc bought a new stake in Becton, Dickinson and Company during the second quarter worth about $29,000. Finally, Atlas Brown Inc. purchased a new stake in Becton, Dickinson and Company in the third quarter worth about $35,000. 86.97% of the stock is currently owned by hedge funds and other institutional investors.
Becton, Dickinson and Company Price Performance
BDX opened at $212.19 on Friday. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.54 and a current ratio of 0.87. The stock has a market capitalization of $58.47 billion, a P/E ratio of 16.41, a P/E/G ratio of 3.63 and a beta of 0.22. The company’s 50-day simple moving average is $194.40 and its two-hundred day simple moving average is $170.85. Becton, Dickinson and Company has a 52-week low of $140.11 and a 52-week high of $220.36.
Becton, Dickinson and Company declared that its board has authorized a stock buyback program on Thursday, November 5th that allows the company to buy back 10,000,000 shares. This repurchase authorization allows the medical instruments supplier to purchase up to 3.6% of its shares through open market purchases. Stock repurchase programs are often a sign that the company’s management believes its stock is undervalued.
Becton, Dickinson and Company Increases Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 31st. Investors of record on Thursday, December 10th will be issued a $1.06 dividend. The ex-dividend date of this dividend is Thursday, December 10th. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $1.05. This represents a $4.24 annualized dividend and a dividend yield of 2.0%. Becton, Dickinson and Company’s dividend payout ratio is presently 101.45%.
Insider Buying and Selling at Becton, Dickinson and Company
In other Becton, Dickinson and Company news, CEO Thomas E. Polen, Jr. sold 2,993 shares of the firm’s stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $210.00, for a total value of $628,530.00. Following the transaction, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at approximately $23,134,230. This trade represents a 2.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Feld sold 165 shares of the business’s stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total value of $31,100.85. Following the sale, the executive vice president owned 19,720 shares of the company’s stock, valued at approximately $3,717,022.80. This represents a 0.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 3,310 shares of company stock valued at $688,650 in the last ninety days. 0.40% of the stock is currently owned by corporate insiders.
Wall Street Analysts Forecast Growth
BDX has been the subject of a number of analyst reports. Bank of America raised their target price on shares of Becton, Dickinson and Company from $185.00 to $200.00 and gave the company a “neutral” rating in a research note on Monday, August 31st. Wells Fargo & Company upped their price target on Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an “equal weight” rating in a research note on Friday, August 7th. TD Cowen raised their price objective on Becton, Dickinson and Company from $163.00 to $182.00 and gave the company a “hold” rating in a research report on Wednesday, August 5th. Stifel Nicolaus set a $195.00 price objective on Becton, Dickinson and Company in a research note on Friday, August 7th. Finally, Weiss Ratings raised Becton, Dickinson and Company from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, November 4th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Becton, Dickinson and Company presently has an average rating of “Moderate Buy” and a consensus target price of $197.47.
Check Out Our Latest Research Report on Becton, Dickinson and Company
Becton, Dickinson and Company Profile
Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops and manufactures products used in healthcare, clinical laboratories and life sciences research. Founded in 1897, the company has a long history of producing medical devices and supplies. BD’s products include syringes, needles, infusion systems and medication-management technologies, as well as equipment and supplies for collecting and processing clinical specimens. The company also provides diagnostic systems, laboratory instruments and tools used in areas such as cell analysis and biomedical research.
Further Reading
- Five stocks we like better than Becton, Dickinson and Company
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.
